MX2014005565A - Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos. - Google Patents
Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos.Info
- Publication number
- MX2014005565A MX2014005565A MX2014005565A MX2014005565A MX2014005565A MX 2014005565 A MX2014005565 A MX 2014005565A MX 2014005565 A MX2014005565 A MX 2014005565A MX 2014005565 A MX2014005565 A MX 2014005565A MX 2014005565 A MX2014005565 A MX 2014005565A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- inflammatory diseases
- compound
- formula
- treating inflammatory
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000006045 Spondylarthropathies Diseases 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 238000011262 co‐therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 201000005671 spondyloarthropathy Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método para tratar o disminuir la severidad de una enfermedad seleccionada de espondiloartropatía, lupus eritematoso sistémico, artritis reumatoide, o cualquier combinación de los mismos que comprende administración de un compuesto de la Fórmula I y una co-terapia opcional (por ejemplo, agente de quimioterapia, DMARD, o cualquier combinación de estos). La presente invención también proporciona una composición farmacéutica que comprende un compuesto de la Fórmula I, un método para elaborar una composición farmacéutica que comprende un compuesto de la Fórmula I, y un método para administrar una composición farmacéutica que comprende una forma sólida de un compuesto de la Fórmula I.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556666P | 2011-11-07 | 2011-11-07 | |
| US201261594818P | 2012-02-03 | 2012-02-03 | |
| US201261636024P | 2012-04-20 | 2012-04-20 | |
| PCT/US2012/063712 WO2013070606A1 (en) | 2011-11-07 | 2012-11-06 | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014005565A true MX2014005565A (es) | 2014-05-30 |
Family
ID=47178996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005565A MX2014005565A (es) | 2011-11-07 | 2012-11-06 | Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140243273A1 (es) |
| EP (1) | EP2776036A1 (es) |
| JP (1) | JP2014532765A (es) |
| AU (1) | AU2012336019A1 (es) |
| CA (1) | CA2854879A1 (es) |
| MX (1) | MX2014005565A (es) |
| WO (1) | WO2013070606A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2537849A3 (en) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| SG10201405826RA (en) | 2009-06-17 | 2014-12-30 | Vertex Pharma | Inhibitors of influenza viruses replication |
| CN106432311A (zh) | 2011-07-05 | 2017-02-22 | 沃泰克斯药物股份有限公司 | 生产氮杂吲哚类的方法和中间体 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2014074471A1 (en) * | 2012-11-06 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
| WO2014201332A1 (en) | 2013-06-14 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical combinations useful for treating rheumatoid arthritis |
| PT3068776T (pt) | 2013-11-13 | 2019-08-26 | Vertex Pharma | Inibidores da replicação de vírus da gripe |
| WO2015073481A1 (en) | 2013-11-13 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005027825D1 (de) | 2004-03-30 | 2011-06-16 | Vertex Pharma | Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole |
| EP2537849A3 (en) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| PH12012502046A1 (en) * | 2010-04-14 | 2017-07-26 | Array Biopharma Inc | 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases |
-
2012
- 2012-11-06 EP EP12787313.1A patent/EP2776036A1/en not_active Withdrawn
- 2012-11-06 WO PCT/US2012/063712 patent/WO2013070606A1/en not_active Ceased
- 2012-11-06 MX MX2014005565A patent/MX2014005565A/es not_active Application Discontinuation
- 2012-11-06 AU AU2012336019A patent/AU2012336019A1/en not_active Abandoned
- 2012-11-06 CA CA2854879A patent/CA2854879A1/en not_active Abandoned
- 2012-11-06 JP JP2014541160A patent/JP2014532765A/ja active Pending
-
2014
- 2014-05-07 US US14/271,589 patent/US20140243273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2776036A1 (en) | 2014-09-17 |
| US20140243273A1 (en) | 2014-08-28 |
| JP2014532765A (ja) | 2014-12-08 |
| AU2012336019A1 (en) | 2014-05-29 |
| WO2013070606A1 (en) | 2013-05-16 |
| CA2854879A1 (en) | 2013-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014005565A (es) | Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos. | |
| CY1121843T1 (el) | Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου | |
| MX363913B (es) | Inhibidores de bromodominio tetraciclicos. | |
| MX357923B (es) | Polipéptidos antiinflamatorios no sialilados. | |
| CY1119974T1 (el) | Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| MX2015012005A (es) | Inhibidores de bromodominio. | |
| MX2015012158A (es) | Inhibidores de bomodominio tetraciclicos fusionados. | |
| UY34037A (es) | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| MX2013008851A (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
| WO2012174158A3 (en) | Administration of benzodiazepine | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| WO2012122383A3 (en) | Pi3 kinase inhibitors and uses thereof | |
| MX343534B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| PH12013500870A1 (en) | Heterocyclic compounds and uses thereof | |
| NZ720478A (en) | Autotaxin inhibitor compounds | |
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| AU2012209332A8 (en) | Methods and compositions for preparing noribogaine from voacangine | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
| WO2013023059A3 (en) | Methods and compositions for the treatment of autoimmune and inflammatory diseases | |
| CA2843611C (en) | Compositions and methods for reducing the incidence of equine digestive disorders | |
| MX2010002559A (es) | Composiciones y metodos para tratar enfermedades y desordenes inmulogicos e inflamatorios. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |